BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Encorafenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Encorafenib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03839342-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Encorafenib: Phase 2 readout est. (NCT03839342)
DESCRIPTION:Encorafenib\, phase 2.\nStudy: Binimetinib and Encorafenib for 
 the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations\nEsti
 mated primary completion: December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03839342
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03803553-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Encorafenib: Phase 3 readout est. (NCT03803553)
DESCRIPTION:Encorafenib\, phase 3.\nStudy: Identification and Treatment Of 
 Micrometastatic Disease in Stage III Colon Cancer\nEstimated primary compl
 etion: December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /encorafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03803553
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05706779-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Encorafenib: Phase 2 readout est. (NCT05706779)
DESCRIPTION:Encorafenib\, phase 2\, Colorectal Cancer.\nStudy: Encorafenib 
 Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Loc
 alised Colon or Upper Rectum Cancer\nEstimated primary completion: 30 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/encorafeni
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 706779
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06102902-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Encorafenib: Phase 1 readout est. (NCT06102902)
DESCRIPTION:Encorafenib\, phase 1\, Colorectal Cancer.\nStudy: Testing the 
 Addition of Anti-cancer Drug\, ZEN003694\, to the Usual Chemotherapy Treat
 ment\, Cetuximab Plus Encorafenib\, for Colorectal Cancer\nEstimated prima
 ry completion: 30 January 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/encorafenib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06102902
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05026983-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Encorafenib: Phase 2 readout est. (NCT05026983)
DESCRIPTION:Encorafenib\, phase 2\, Melanoma.\nStudy: Binimetinib and Encor
 afenib for the Treatment of Metastatic Melanoma and Central Nervous System
  Metastases\nEstimated primary completion: 2 February 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/encorafenib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05026983
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270044-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Encorafenib: Phase 3 readout est. (NCT05270044)
DESCRIPTION:Encorafenib\, phase 3\, Melanoma.\nStudy: Adjuvant Encorafenib 
 and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.\nEsti
 mated primary completion: 31 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05270044
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04741997-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Encorafenib: Phase 1 readout est. (NCT04741997)
DESCRIPTION:Encorafenib\, phase 1\, Melanoma.\nStudy: Adjuvant Therapy Base
 d on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Mela
 noma\nEstimated primary completion: April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04741997
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06411600-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Encorafenib: Phase 2 readout est. (NCT06411600)
DESCRIPTION:Encorafenib\, phase 2\, Colorectal Cancer.\nStudy: Combination 
 Therapy for BRAF-V600E Metastatic CRCm\nEstimated primary completion: 1 Ma
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/encorafenib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06411
 600
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Encorafenib: Phase 3 readout est. (NCT05615818)
DESCRIPTION:Encorafenib\, phase 3.\nStudy: Personalized Medicine for Advanc
 ed Biliary Cancer Patients\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/encorafenib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05615818
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04511013-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Encorafenib: Phase 2 readout est. (NCT04511013)
DESCRIPTION:Encorafenib\, phase 2\, Melanoma.\nStudy: A Study to Compare th
 e Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimuma
 b + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04511013
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318389-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Encorafenib: Phase 1 readout est. (NCT07318389)
DESCRIPTION:Encorafenib\, phase 1\, Colorectal Cancer.\nStudy: ASCEND-CRC: 
 Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastat
 ic Colorectal Cancer\nEstimated primary completion: 14 November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/encorafenib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07318389
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02910700-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20271208
DTEND;VALUE=DATE:20271209
SUMMARY:Encorafenib: Phase 2 readout est. (NCT02910700)
DESCRIPTION:Encorafenib\, phase 2\, Melanoma.\nStudy: Nivolumab With Tramet
 inib and Dabrafenib\, or Encorafenib and Binimetinib in Treating Patients 
 With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma\nEstima
 ted primary completion: 8 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT02910700
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04017650-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Encorafenib: Phase 1/2 readout est. (NCT04017650)
DESCRIPTION:Encorafenib\, phase 1/2\, Colorectal Cancer.\nStudy: Encorafeni
 b\, Cetuximab\, and Nivolumab in Treating Patients With Microsatellite Sta
 ble\, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer\nEsti
 mated primary completion: 30 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04017650
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04061980-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Encorafenib: Phase 2 readout est. (NCT04061980)
DESCRIPTION:Encorafenib\, phase 2.\nStudy: Encorafenib and Binimetinib With
  or Without Nivolumab in Treating Patients With Metastatic Radioiodine Ref
 ractory BRAF V600 Mutant Thyroid Cancer\nEstimated primary completion: 30 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/encora
 fenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04061980
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887088-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Encorafenib: Phase 2 readout est. (NCT06887088)
DESCRIPTION:Encorafenib\, phase 2\, Melanoma.\nStudy: Encorafenib and biNim
 etinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant m
 elanOma and Symptomatic Brain Metastases\nEstimated primary completion: Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/encorafen
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6887088
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06194929-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Encorafenib: Phase 1/2 readout est. (NCT06194929)
DESCRIPTION:Encorafenib\, phase 1/2\, Melanoma.\nStudy: Defactinib and Avut
 ometinib\, With or Without Encorafenib\, for the Treatment of Patients Wit
 h Brain Metastases From Cutaneous Melanoma\nEstimated primary completion: 
 15 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enco
 rafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06194929
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178717-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Encorafenib: Phase 2 readout est. (NCT07178717)
DESCRIPTION:Encorafenib\, phase 2\, Colorectal Cancer.\nStudy: A Study to C
 haracterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V
 600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W
 ith BRAF Inhibitors-based Combinations\nEstimated primary completion: Febr
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/encorafeni
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 178717
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05985954-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20280328
DTEND;VALUE=DATE:20280329
SUMMARY:Encorafenib: Phase 1 readout est. (NCT05985954)
DESCRIPTION:Encorafenib\, phase 1\, Colorectal Cancer.\nStudy: Open-label P
 hase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination W
 ith Cetuximab and Encorafenib in Patients With Unresectable or Metastatic 
 Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Thera
 py\nEstimated primary completion: 28 March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05985954
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04903119-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Encorafenib: Phase 1 readout est. (NCT04903119)
DESCRIPTION:Encorafenib\, phase 1\, Melanoma.\nStudy: Nilotinib Plus Dabraf
 enib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma\nEstimat
 ed primary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04903119
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207656-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Encorafenib: Phase 2 readout est. (NCT06207656)
DESCRIPTION:Encorafenib\, phase 2\, Colorectal Cancer.\nStudy: Study to Eva
 luate the Efficacy and Safety of Cetuximab in Combination with Encorafenib
  Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initial
 ly Resectable or Potentially Resectable Advanced Colorectal Cancer\nEstima
 ted primary completion: 1 April 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06207656
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05203172-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Encorafenib: Phase 4 readout est. (NCT05203172)
DESCRIPTION:Encorafenib\, phase 4.\nStudy: The FLOTILLA Study: Providing Co
 ntinued Access to The Study Medicines Encorafenib and Binimetinib for Part
 icipants in Prior Clinical Trials\nEstimated primary completion: 31 July 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/encorafenib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05203172
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789210-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Encorafenib: Phase 2 readout est. (NCT07789210)
DESCRIPTION:Encorafenib\, phase 2\, Colorectal Cancer.\nStudy: A Single-Arm
 \, Phase II\, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus C
 etuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mut
 ant Colorectal Cancer With or Without Resectable Metastases\nEstimated pri
 mary completion: 31 December 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/encorafenib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07789210
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05710406-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20340601
DTEND;VALUE=DATE:20340602
SUMMARY:Encorafenib: Phase 2/3 readout est. (NCT05710406)
DESCRIPTION:Encorafenib\, phase 2/3.\nStudy: Testing the Use of BRAF-Target
 ed Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Can
 cer\nEstimated primary completion: 1 June 2034. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/encorafenib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05710406
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-2219@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Encorafenib: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Encorafenib\, phase 2\, Colorectal Cancer.\nStudy: Study to Inv
 estigate Outcome of Individualized Treatment in Patients With Metastatic C
 olorectal Cancer\nEstimated primary completion: 31 December 2038. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/encorafenib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/encorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
